NCT07465458Not yet recruiting
Radiofrequency Ablation Multicenter Observational Study in Renal Oncology Patients
Source: ClinicalTrials.gov · Last updated 16 Mar 2026
Brief summary (registry, in English)
This observational study is designed to expand the current database available in the literature and the existing knowledge on the outcomes and safety of radiofrequency ablation (RFA) for the treatment of primary renal cell carcinomas in stage T1a. All interventions and subsequent follow-ups are clinical decisions are independent of the study, given its observational nature.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 226 (estimated)
- First submitted
- 6 Mar 2026
- Start date
- 1 Mar 2026
- Primary completion date
- 31 Mar 2028
- Lead sponsor
- Humanitas Hospital, Italy
- Diseases
- Kidney cancer
- NCT number
- NCT07465458
What you commit to
- Study type: Observational
- Planned participants: 226
- From 1 Mar 2026 to the primary completion date, 31 Mar 2028
- 10 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- No specific exclusion criteria are established for this clinical registry due to its observational nature. Each center will apply its own criteria according to its routine clinical practice.
Who the study is looking for
- Age ≥18 years
- Signed informed consent approved by the Ethics Committee prior to the ablation procedure.
- RCC in stage T1a (size \<4 cm), single or multiple, histologically demonstrated by percutaneous biopsy before or within 30 days prior to ablation
- Absence of comorbidities that contraindicate treatment
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2 at baseline screening.
Criteria the registry did not label
- Patient selection criteria will be those typically established by each participating center t with T1a primary renal tumors for which a Multidisciplinary Tumor Board has indicated as candidates for treatment with radiofrequency ablation.I
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Clínico Universitario Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
| Hospital Universitario Reina Sofia Coordinator of this site? Confirm its status | Córdoba | Spain | Unknown status |
| Hospital Universitario de Leganés (Severo Ochoa) Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| Hospital Universitario Puerta de Hierro Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| Hospital Universitario Fundación Jiménez Díaz Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| Hospital Universitario Donostia Coordinator of this site? Confirm its status | San Sebastián | Spain | Unknown status |
| Fondazione Poliambulanza Istituto Ospedaliero Coordinator of this site? Confirm its status | Brescia | Italy | Unknown status |
| IRCCS Ospedale San Raffaele Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
| Istituto Europeo di Onclologia ( IEO) Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
| Policlinico Universitario Campus Bio-Medico Coordinator of this site? Confirm its status | Roma | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.